KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $189.5 million.

  • Arbutus Biopharma's Shares Outstanding (Weighted Average) rose 1.54% to $191.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.7 million, marking a year-over-year increase of 1.54%. This contributed to the annual value of $189.5 million for FY2024, which is 13.00% up from last year.
  • Per Arbutus Biopharma's latest filing, its Shares Outstanding (Weighted Average) stood at $189.5 million for FY2024, which was up 13.00% from $167.7 million recorded in FY2023.
  • Arbutus Biopharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $189.5 million during FY2024, with a 5-year trough of $95.6 million in FY2020.
  • Over the past 3 years, Arbutus Biopharma's median Shares Outstanding (Weighted Average) value was $167.7 million (recorded in 2023), while the average stood at $171.2 million.
  • Data for Arbutus Biopharma's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 68.13% (in 2020) over the last 5 years.
  • Arbutus Biopharma's Shares Outstanding (Weighted Average) (Yearly) stood at $95.6 million in 2020, then soared by 41.52% to $135.3 million in 2021, then climbed by 15.67% to $156.5 million in 2022, then climbed by 7.18% to $167.7 million in 2023, then rose by 13.00% to $189.5 million in 2024.